Thymos Health
Your Psoriasis Journey

Still flaking.
Still switching cream after cream.
Still no clear skin.

You're not alone. This is how psoriasis is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

8M Americans are living with plaque psoriasis.1
30% also develop psoriatic arthritis — often undiagnosed for years.2
1.6 years is the average delay before an accurate psoriasis diagnosis.3
$112B is the estimated annual U.S. economic burden of psoriasis.1

How psoriasis is typically treated

Most insurance plans require step therapy — starting with topical steroids, then phototherapy or oral pills, before approving a high-efficacy biologic. Each failed step can take 3–6 months to document, while skin damage, joint symptoms, and cardiometabolic risk can build quietly in the background.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your dermatologist starts you on Topical Corticosteroids
Betamethasone, clobetasol, calcipotriene — applied 1–2× daily to plaques
What your doctor says
"Let's start with a topical steroid. For plaques covering less than 10% of your body, this is usually enough to keep things under control."
Effective for mild, limited-area disease
Skin thinning & rebound flares with prolonged use
Rarely controls moderate-to-severe disease alone
Annual cost before insurance (retail) ~$600–$2,000
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
~20% have moderate-to-severe disease needing systemic therapy — escalate to Step 2
Step 2: You move to Phototherapy or Oral Systemics
Narrowband UVB (2–3×/week in-office) or methotrexate / apremilast pills
What your doctor says
"Since topicals aren't enough, let's try light therapy or a pill like methotrexate. These treat your whole body's inflammation, not just the visible patches."
Methotrexate: modest efficacy, decades of use
Only 12.4% of psoriasis patients respond to Apremilast4
Phototherapy requires 2–3 clinic visits/week
Annual cost before insurance ~$3,000–$15,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Inadequate response or intolerance — insurer now allows a biologic
Step 3: You're approved for Biologic Therapy
TNF, IL-17, or IL-23 inhibitors (e.g. adalimumab, secukinumab, guselkumab, risankizumab) — injection or infusion
What your doctor says
"Now that you've failed two prior therapies, your insurance will cover a biologic. The newer IL-17 and IL-23 drugs can get most patients to completely clear or almost-clear skin."
65–73% psoriasis patients respond to newer biologics5
18% response rate to etanercept5
43% response rate to adalimumab5
Net U.S. price ranges $1,664–$79,277/yr by agent6
Annual cost before insurance (net, US) ~$35,000 (median)
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
When skin clearing stops being the only issue Psoriatic Arthritis & Comorbidity Onset
Joint damage, cardiometabolic disease, and diagnostic delay compound while skin is treated in isolation
What Your Doctor says
"Your skin looks great on the biologic. The joint pain you mentioned — let's keep an eye on it and see your primary care doctor about that."
27% undergo a joint surgery during the diagnostic delay period8
~40%
Of psoriasis patients develop psoriatic arthritis2
2.5 yr
Median symptom-to-diagnosis delay for psoriatic arthritis7
9%
Of psoriasis patients have undiagnosed psoriatic arthritis right now2
$135B
Annual U.S. cost of psoriatic disease (skin + joints)9
Diagnostic delay milestones for psoriatic arthritis
Diagnosed within 6 months of joint symptoms 23% of patients
Diagnosed within 1 year 35% of patients
Diagnosed within 2 years 45% of patients
Still undiagnosed with psoriatic arthritis despite active psoriasis care 9% of PsO patients
What changes when joint disease goes unaddressed
🦴 Irreversible joint damage accrues silently. Delays of even 6–12 months in psoriatic arthritis diagnosis are associated with structural joint damage and worse long-term function — damage that later biologic therapy cannot reverse.7
🔪 Surgery rates spike before diagnosis. In one cohort, 27.4% of psoriatic arthritis patients underwent at least one musculoskeletal surgery during their diagnostic delay period — a significantly higher annual surgery rate than after diagnosis and treatment began.8
❤️ Cardiometabolic risk rides along with skin severity. Patients with more severe, longer-duration psoriasis carry meaningfully higher rates of comorbid cardiovascular disease, diabetes, and obesity — conditions that are rarely coordinated with dermatologic care.10
💰 Costs escalate well before anyone treats the joints. Annual per-patient costs are already nearly 3× higher for psoriatic arthritis (~$30,000) than for psoriasis alone (~$11,000) — largely driven by care that starts after damage is already visible on imaging.9
⚠ Skin clearance is not the same as disease control
A biologic that clears skin doesn't automatically screen for or treat joint, cardiovascular, or metabolic disease. Dermatology-only management of psoriasis, without coordinated screening for psoriatic arthritis and comorbidities, is the default pathway for most patients — and it is where the diagnostic delay above originates.

What psoriasis is really costing you

Psoriasis is a whole-body inflammatory disease, but insurance economics treat it as a skin problem. The drug bill is only part of it — missed work and reduced productivity from itching, pain, and visible flares add up fast.

Based on your journey above–adjust the numbers to match your situation.
Work days affected by flares in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of psoriasis $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Presenteeism from psoriasis symptoms estimated at ~$2,961/worker/year (~102 hours of reduced output annually).11 Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
If your care reaches the last phase of this journey — Biologic Therapy
$0
Projected patient out-of-pocket cost for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).

What your insurer is paying

Psoriasis is one of the most biologic-driven categories in commercial insurance. A single patient's spend can range from a few hundred dollars a year on topicals to tens of thousands once a biologic is approved — and that spend keeps climbing if psoriatic arthritis develops.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your psoriasis each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your psoriasis care $0
Biologic / systemic drug spend (payer portion)
~80% of net price after patient coinsurance; biologics drive the overwhelming majority of psoriasis pharmacy spend
$0
Medical costs (dermatology visits, phototherapy, labs)
Baseline non-drug medical costs for a managed psoriasis patient
~$3,500
Do you have joint pain, swelling, or stiffness that hasn't been formally evaluated?
Undiagnosed joint symptoms in a psoriasis patient are one of the strongest predictors of future high-cost claims once psoriatic arthritis is finally diagnosed
Comprehensive psoriatic disease (skin + joints + comorbidities) costs the U.S. system an estimated $135 billion/year — with biologic pharmacy spend as the single largest driver.
Payer cost projection if care reaches the last phase of this journey — Biologic Therapy
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ What step therapy costs your plan in the long run
Requiring 6–12 months of topical and oral failure before approving a biologic delays skin clearance — but it also delays the moment a dermatologist starts screening for joint symptoms. Since a 6–12 month delay in psoriatic arthritis diagnosis is linked to irreversible joint damage and higher surgery rates, the near-term savings from step therapy can convert into a much larger, harder-to-treat claim years later.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented trajectory for patients whose psoriatic disease is managed skin-first, without coordinated screening for joint and cardiometabolic involvement.

Based on peer-reviewed clinical data
Long-term outcomes for psoriasis patients on standard step therapy
🦴
~40% of psoriasis patients eventually develop psoriatic arthritis — often diagnosed years after joint symptoms begin2
⏳
2.5 yr median delay from first joint symptom to a confirmed psoriatic arthritis diagnosis, during which structural damage can accumulate7
🔪
27% of eventual psoriatic arthritis patients underwent at least one musculoskeletal surgery during their pre-diagnosis delay period8
💊
~65–73% PASI90 (near-total skin clearance) achievable with today's best biologics — when patients actually reach that step of the ladder5
✦ A different journey exists

Thymos Health offers another way

Conventional psoriasis care treats the skin you can see. Thymos goes further – synthesizing your labs, joint symptoms, cardiometabolic risk, and treatment history to catch psoriatic arthritis and comorbidities early, and to coordinate dermatology, rheumatology, and primary care around one plan.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Brezinski EA, Dhillon JS, Armstrong AW. "Economic Burden of Psoriasis in the United States: A Systematic Review." JAMA Dermatology, 2015;151(6):651–658. Direct costs $51.7B–$63.2B, indirect costs $23.9B–$35.4B, comorbidity-attributable costs ~$36.4B; total annual U.S. cost of psoriasis ≈ $112 billion (2013 USD). ~8 million Americans affected.
PMID: 25565304
[2] Rheumatology Advisor. "Psoriatic Arthritis: Overcoming Challenges of Differential Diagnosis." 2024. Of 8 million Americans with psoriasis, 30%–33% are reported to also have psoriatic arthritis; undiagnosed psoriatic arthritis reported in 9% of psoriasis patients; rates as high as 41% reported in some cohorts.
Source: rheumatologyadvisor.com
[3] Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK. British Journal of General Practice / PMC, 2022. Multicentre international observational study: average diagnostic delay for psoriasis estimated at 1.6 years (SD 4.8).
PMC: PMC9550319
[4] Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy, 2021. Apremilast PASI90 response rate 12.4% (SUCRA 0.090) vs. ixekizumab 72.9%, risankizumab 72.5%, brodalumab 72.0%.
DOI: 10.1007/s13555-021-00511-1
[5] Same network meta-analysis (Dermatology and Therapy, 2021): full PASI90 ranking — ixekizumab 72.9%, risankizumab 72.5%, brodalumab 72.0%, guselkumab 65.0%, secukinumab 65.0%, infliximab 56.8%, ustekinumab ~46–48%, adalimumab 43.0%, etanercept 18.0%.
DOI: 10.1007/s13555-021-00511-1
[6] Egilman AC et al. Efficiency-frontier cost analysis of psoriasis biologics, summarized in Dermatology Times, 2024. Net annual U.S. treatment costs ranged from $1,664 (infliximab-dyyb) to $79,277 (risankizumab); median net annual cost across 13 biologics was $34,965 — over 3× peer-country pricing.
Source: dermatologytimes.com
[7] Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. The Journal of Rheumatology, 2021. Olmsted County cohort (n=164): median time from symptom onset to psoriatic arthritis diagnosis was 2.5 years (IQR 0.5–7.3); >50% had diagnostic delay >2 years.
Source: jrheum.org
[8] Increased Musculoskeletal Surgery Rates During Diagnostic Delay in Psoriatic Arthritis: A Retrospective Cohort Study. 2024/2025 (n=84). Mean diagnostic delay 7.49 years; 27.4% underwent ≥1 musculoskeletal surgery during the delay period, at a significantly higher annual rate than post-diagnosis.
PMC: PMC12071673
[9] Employer Health Innovation Co. "Soaring Psoriasis: Market Trends and Opportunities for Psoriatic Conditions," 2023, citing Merola JF et al. All-cause annual healthcare costs per psoriatic arthritis patient ~$30,000 vs. ~$11,000 for plaque psoriasis alone; cost of psoriatic disease overall (skin + joints) reported at $135 billion/year (2013 estimate).
Source: employershealthco.com
[10] Economic burden of comorbidities in psoriasis patients in the United States. Journal of Medical Economics / PMC, retrospective claims database (n=56,406). Cardiovascular disease, diabetes, and psoriatic arthritis were among the most prevalent comorbidities and independently increased direct and indirect costs.
PMC: PMC5422993
[11] American Autoimmune Related Diseases Association (AARDA), compiled economic burden report. Lost productivity ("presenteeism") among patients with psoriasis estimated at approximately $9.9 billion nationally, or $2,961 per affected worker annually.
Source: diabetesed.net (AARDA PDF)